HC Wainwright Issues Positive Forecast for IOVA Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Equities researchers at HC Wainwright boosted their Q3 2026 earnings per share (EPS) estimates for Iovance Biotherapeutics in a research report issued on Thursday, August 6th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings of ($0.12) per share for the quarter, up from their previous forecast of ($0.17). The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for Iovance Biotherapeutics’ Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.58) EPS and FY2027 earnings at ($0.35) EPS.

IOVA has been the topic of several other reports. Chardan Capital decreased their price objective on shares of Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research report on Thursday, July 2nd. Citigroup reissued an “outperform” rating on shares of Iovance Biotherapeutics in a research note on Friday. Robert W. Baird set a $6.00 price target on shares of Iovance Biotherapeutics in a report on Friday. Finally, Barclays raised their price objective on shares of Iovance Biotherapeutics from $11.00 to $13.00 and gave the company an “overweight” rating in a research report on Friday. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $8.00.

Iovance Biotherapeutics Trading Up 1.4%

Shares of IOVA opened at $6.49 on Monday. Iovance Biotherapeutics has a 12-month low of $1.76 and a 12-month high of $6.92. The company has a market cap of $2.94 billion, a PE ratio of -8.89 and a beta of 0.71. The stock has a 50-day moving average price of $4.50 and a 200-day moving average price of $3.87.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. Iovance Biotherapeutics had a negative return on equity of 40.92% and a negative net margin of 89.11%.The business had revenue of $198.63 million for the quarter, compared to analyst estimates of $87.83 million. During the same period in the prior year, the company earned ($0.33) EPS. The company’s quarterly revenue was up 65.7% compared to the same quarter last year.

Institutional Trading of Iovance Biotherapeutics

Hedge funds have recently bought and sold shares of the company. Arcataur Capital Management LLC purchased a new stake in Iovance Biotherapeutics in the fourth quarter worth approximately $29,000. Granite Investment Partners LLC bought a new stake in shares of Iovance Biotherapeutics in the 4th quarter worth approximately $29,000. Motley Fool Asset Management LLC bought a new stake in shares of Iovance Biotherapeutics in the 4th quarter worth approximately $29,000. M&T Bank Corp purchased a new stake in shares of Iovance Biotherapeutics in the 4th quarter valued at $31,000. Finally, SBI Securities Co. Ltd. boosted its stake in shares of Iovance Biotherapeutics by 169.1% in the 4th quarter. SBI Securities Co. Ltd. now owns 11,568 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 7,269 shares in the last quarter. Institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.